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Abstract The relationship between the kidney and bone
is highly complex, and the kidney plays an important role
in the regulation of bone development and metabolism.
The kidney is the major organ involved in the regulation of
calcium and phosphate homeostasis, which is essential for
bone mineralization and development. Many substances
synthesized by the kidney, such as 1,25(OH)2D3, Klotho,
bone morphogenetic protein-7, and erythropoietin, are
involved in different stages of bone formation, remodeling
and repair. In addition, some cytokines which can be
affected by the kidney, such as osteoprotegerin, sclerostin,
fibroblast growth factor -23 and parathyroid hormone, also
play important roles in bone metabolism. In this paper, we
summarize the possible effects of these kidney-related
cytokines on bone and their possible mechanisms. Most of
these cytokines can interact with one another, constituting
an intricate network between the kidney and bone. There-
fore, kidney diseases should be considered among patients
presenting with osteodystrophy and disturbances in bone
and mineral metabolism, and treatment for renal dysfunc-
tion may accelerate their recovery.
Keywords Kidney  Bone  1,25(OH)2D3  Klotho  Bone
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Introduction
The relationship between the kidney and bone is a field that
has been explored for a very long time. Over 2000 years
ago, the earliest Chinese medical literature ‘Huangdi Nei-
jing’ systematically expounded the theory ‘‘shen zhu gu’’
(kidney controls bone) from the perspective of traditional
Chinese medicine. In 1943, two Chinese physicians intro-
duced the term ‘‘renal osteodystrophy’’ to describe the
cases of osseous disorder associated with renal insuffi-
ciency [1]. All bone abnormalities related to chronic kid-
ney disease (CKD) ultimately lead to an increased risk of
fracture, which has become an important cause of mor-
bidity and decreased quality of life [2]. Hence, normal
function of kidney is important for bone health, and to
illustrate the potential relationships between kidney and
bone becomes an urgent issue. In this review, we recapit-
ulate the possible links between the kidney and bone with a
main focus on the role of the kidney.
The kidney is the major organ for homeostasis
of calcium and phosphate
The homeostasis of calcium and phosphate is complicated. In
calcium and phosphate balance, more than 97 % of calcium
and 80 % of phosphate filtered in the kidney are reabsorbed
at different segments of the tubules, and their homeostasis
can be severely affected in kidney diseases [3, 4]. The
majority of the calcium and phosphate in our body resides in
bone, and these two elements are critical for the normal
structure and function of bone [5]. Calcium and phosphate
are the main components of bone minerals. Beyond that, they
also have some biological effects. Calcium can directly
stimulate osteoblast formation while inhibiting osteoclast
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formation via calcium-sensitive receptor (CaSR) dependent
or independent pathways [6, 7]. However, phosphate can
directly promote osteoclast apoptosis and inhibit its differ-
entiation by affecting receptor activator of nuclear factor-jB
(RANK)-RANK ligand (RANKL) signaling and osteopro-
tegerin (OPG) [8, 9]. This indicates that the kidney may
affect the structure and function of bone by regulating the
homeostasis of calcium and phosphate.
The kidney regulates bone health by generating
activated vitamin D
1,25(OH)2D3 is the activated pattern of vitamin D, and the
circulating 1,25(OH)2D3 (calcitriol) is mainly produced in
the proximal renal tubules under the hydroxylation of 1a-
hydroxylase [1a(OH)ase], which is encoded by cyp27b1
[10]. It regulates the homeostasis of calcium and phos-
phate, and bone development and repair by binding vitamin
D receptor (VDR) located in the intestine, kidney and bone.
1,25(OH)2D3 promotes calcium and phosphate uptake
and reabsorption by increasing the expression of their
transport proteins in enterocytes and renal tubule cells [3,
11]. Apart from that, direct effects on bone are also
observed. Chondrocyte-specific vdr inactivation in mice
shows that 1,25(OH)2D3 controls vascular invasion and
osteoclast formation by increasing vascular endothelial
growth factor (VEGF) and RANKL [12]. For osteoblast,
1,25(OH)2D3 affects the synthesis of collagen I and
expression of alkaline phosphatase (ALP), osteocalcin and
osteopontin [13, 14], stimulates bone matrix mineralization
via accelerating the production of mature micro vesicles and
modulates the bone microenvironment by regulating the
osteoblastic niche [15, 16]. For osteoclast, 1,25(OH)2D3
plays bidirectional roles. On the one hand, it stimulates
osteoclastogenesis by increasing the expression of RANKL
on chondrocyte and osteoclast [12, 17]. On the other hand, in
osteoclast precursors, 1,25(OH)2D3 directly suppresses the
expression of RANK via down-regulation of c-Fms, inhibits
key regulators of osteoclast formation, c-Fos and NFATc1,
and increases its inhibitor, CCAAT enhancer-binding pro-
teins [18–21]. Therefore the comprehensive effects of
1,25(OH)2D3 on osteoclast, osteoclastogenesis and bone
resorption need to be further investigated.
In addition, 1,25(OH)2D3 can stimulate fibroblast
growth factor (FGF)-23 secretion in osteocytes via binding
vitamin D response element (VDRE) [22]. Reversely, FGF-
23 suppresses 1,25(OH)2D3 levels via its effects on the
kidney to stimulate CYP24A1-mediated degradation and
suppress 1a(OH)ase-mediated production [23]. The nega-
tive feedback loop between them plays an important role in
the crosstalk between the kidney and bone (Fig. 1).
The kidney maintains bone formation
and remodeling by producing Klotho
Klotho is identified as an ‘‘aging suppressor’’ protein,
which is primarily expressed in renal distal convoluted
tubules [24]. It can be divided into membrane-binding and
soluble forms. Membrane-binding Klotho forms a complex
with FGF receptors (FGFRs) and functions as an essential
co-receptor for FGF-23 [25]. The Klotho/FGFR/FGF-23
complex, except for its effect on 1,25(OH)2D3 mentioned
above, can suppress sodium-phosphate (NaPi) co-transport
activity in kidney and reduce phosphate reabsorption [26].
Furthermore, as for proximal tubule epithelial cells
(PTEC), exposure to both FGF-23 and Klotho initiates Ras
and phosphatidylinositol 3-kinase (PI3K) signaling path-
ways manifested by up-regulation in phosphorylation of
ERK1/2, p38, JNK, AKT, IkB and GSK-3b. Combined
application of FGF-23 and Klotho rescues high
1,25(OH)2D3-induced apoptosis of PTEC, while PI3K
inhibitor prevents the effect of FGF-23 and Klotho [27].
Therefore, both Ras and PI3K signaling pathways may be
involved in the crosstalk between the kidney and bone.
Different from membrane-binding Klotho, soluble Klo-
tho can be released into the circulation and act on remote
organs in FGF-23 dependent and independent ways. Sol-
uble Klotho interacts with the FGFRs in osteoblast and
facilitates FGF-23 induced proliferation and inhibition of
mineralization [28]. In addition, it can exert phosphaturic
effects independently. In normal and Fgf23-/- mice, sol-
uble Klotho is able to inactivate NaPi-IIb in the intestine
and NaPi-IIa in the proximal renal tubules to reduce
phosphate absorption and reabsorption [24]. Furthermore,
it can also activate calcium channels transient receptor
potential vanilloid receptor (TRPV) 5/6 and conserve
serum calcium and reduce calciuria [29, 30]. Since soluble
Klotho can inhibit IGF-1, Wnt and transforming growth
factor-b (TGF-b) signaling pathways in aging and in cer-
tain cancers [31], whether these pathways are involved in
the Klotho-induced regulation of bone formation still needs
to be investigated.
In addition, direct effects of Klotho on bone formation
and remodeling are also observed. Klotho deficient mice
show low bone formation and bone resorption activities,
which result in osteopenia [32]. Histological studies show
that the expression of osteocalcin and dentinmatrix protein-
1 (DMP-1) were weak and uneven in the tibiae matrix of
the Klotho-/- mice, and matrix Gla protein (MGP)
expressed in the cartilage cores and bone surfaces, which
were different from wild type mice whose MGP mainly
expressed at the junction between cartilage and bone [32].
Furthermore, the Klotho-/- mice fail to have formed
compact bone in lumbars manifested as abundant
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osteocytes, pyknotic osteocytes and random empty lacunae
[33]. Although osteoblasts from these mice proliferate
normally in vitro, their ability to produce ALP and to
mineralize extracellular matrix is reduced. Moreover, the
low bone resorption activities related to the impaired
osteoclastogenesis appears to be associated with up-regu-
lation of OPG synthesis, which can suppress osteoclast
differentiation [34, 35] (Fig. 2). However, Klotho overex-
pression can also result in reduced bone mineral content,
expanded growth palates and fracture [36]. Therefore,
kidney derived Klotho acts on bone either independently or
in cooperation with bone derived FGF-23, and both the
pathological increase and decrease of Klotho can cause
disturbed bone development and metabolism; hence, a
desired range of circulating Klotho is critical for bone
health.
The kidney modulates bone development
by producing bone morphogenetic protein-7
Bone morphogenetic protein-7 (BMP-7), a member of the
TGF-b superfamily, was originally isolated from dem-
ineralized bone based on its ability to induce new bone
formation. The kidney has been identified as the major site
for BMP-7 synthesis during embryonal and postnatal
development [37]. As a determinant of the embryogenesis
of bone, the effects of BMP-7 on bone have been widely
investigated in different types of animal models. It has
been demonstrated that BMP-7 can induce bone formation,
enhance incomplete fracture and bone defects, even
ameliorate osteonecrosis, osteoarthritis and intervertebral
disc degeneration [38–40]. Mechanisms underlying the
beneficial effects of BMP-7 on bone are sophisticated. For
chondrocytes, BMP-7 can promote chondrocyte differen-
tiation from bone marrow mesenchymal stem cells
(BMMSCs) and exert anabolic effects by stimulating syn-
thesis of extracellular matrix proteins [41]. In addition,
BMP-7 can exert anti-catabolic effects on chondrocytes by
blocking metalloproteinase (MMP)-1, MMP-13 and a
Fig. 1 Actions of 1,25(OH)2D3 on calcium and phosphate home-
ostasis and bone development. 1,25(OH)2D3 synthesized by the
kidney promotes the absorption and reabsorption of calcium and
phosphate in the intestine and kidney, stimulates FGF-23 production
in bone, which inhibits 1,25(OH)2D3 synthesis and phosphate
reabsorption in kidney. 1,25(OH)2D3 exerts osteogenic effects on
osteoblasts and chondrocytes and inhibits osteoclast differentiation
while promoting its maturation by up-regulating RANKL expression
in osteoblasts. : produce or promote; : inhibit, 1a-(OH)ase: 1a-
hydroxylase, Ca2?: calcium, FGF: fibroblast growth factor, PO4:
phosphate, RANKL: receptor activator of nuclear factor NF-jb
ligand, VDR: vitamin D receptor
Fig. 2 Actions of Klotho on calcium and phosphate homeostasis and
bone. The complex of Klotho and FGF-23 inhibits 1,25(OH)2D3
synthesis and phosphate reabsorption in the kidney. Soluble Klotho
stimulates calcium reabsorption and resorption in the kidney and
bone, inhibits calcium and phosphate absorption in intestine and
regulates bone formation and remodeling. : produce or promote,
: inhibit, 1a(OH)ase: 1a-hydroxylase, Ca2?: calcium, FGF:
fibroblast growth factor, PO4: phosphate
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disintegrin and metalloproteinase with thrombospondin
motifs (ADAMTMS) that destroy the extracellular matrix
and cartilage [40, 42]. In some cases, BMP-7 can also
promote chondrocyte maturation manifested by hypertro-
phy and increased expression of ALP [43]. For osteoblasts,
BMP-7 is capable of inducing its differentiation from
BMMSCs by expressing osteoblast differentiation markers,
such as ALP and Runx2, stimulating the proliferation of
mature osteoblasts, inducing collagen synthesis and
enhancing its activity by expressing osteocalcin [41, 44,
45]. The potential mechanisms involved in the above
processes are far more complicated. As members of the
TGF-b superfamily, BMP-7 can activate canonical sig-
naling including Smad1/4/5/8 and non-canonical TAK1/
MKK/p38 signaling. In addition, the interplay between
BMPs and Notch, Hh, FGF as well as Wnt signaling also
plays a very important role in osteoblast and bone [46].
However, whether those signaling pathways are involved
in the BMP-7 induced bone development still needs to be
investigated.
There is a relatively low level of BMP-7 production in
bone, and it seems not to be required for skeletal home-
ostasis because conditional deletion of BMP-7 from the
limb skeleton has no effect on postnatal limb growth,
articular cartilage formation, maintenance of bone mass,
or fracture healing [47]. The results above suggest that
extra-skeletal derived BMP-7 may be more important in
bone formation and growth. The kidney is the major site
of BMP-7 synthesis, and BMP-7 produced in the kidney
is constantly released into the circulation, functioning at
distant sites in a hormone-like manner [48]. Furthermore,
in rat models of osteodystrophy due to renal mass abla-
tion, administration of recombinant BMP-7 can success-
fully inhibit the bone disorder [49] (Fig. 3). All of the
above indicate that BMP-7, which is required for normal
bone development and metabolism, originates from the
kidney.
The kidney promotes bone development
and fracture healing by synthesizing
erythropoietin
Erythropoietin (EPO) is a 30.4kD glycoprotein and class I
cytokine that is characterized by its role in the regulation of
red blood cell production in bone marrow due to its
expression of EPO receptor (EPO-R) [50]. Approximately
90 % of systemic EPO in adults is produced by peritubular
interstitial fibroblasts in the renal cortex and outer medulla
of the kidney [51]. In recent years, with the identification of
non-hematopoietic EPO-R and CD131, the non-he-
matopoietic effects of EPO have begun to be investigated.
Recent studies indicate that EPO plays an important role
in bone formation, fracture healing and intervertebral disc
degeneration. In fracture models of mice, it has been found
that the terminally differentiated chondrocytes within the
callus expressed EPO-R and that administration of
recombined EPO is capable of stimulating endochondral
ossification, cell proliferation and VEGF-mediated angio-
genesis [52]. A rabbit model of autograft posterolateral
spinal fusion also shows that systemic EPO administration
can increase bone volume and neovascularization [53].
First, EPO can increase BMP2 expression by hematopoi-
etic stem cells (HSCs) through the JAK2/Stat3 signaling
pathway. Then, EPO can induce osteoblasts differentiation
from BMMSCs in vitro and bone formation in vivo either
directly or indirectly by the expression of BMP-2 by HSCs
[54]. In addition, EPO can increase osteoclast numbers, but
its effects on osteoclast activity still need to be investigated
[55]. Further investigations demonstrate that the osteogenic
and osteoclastogenesis effects of EPO can be mediated by
three intracellular signaling pathways: mammalian target
of rapamycin (mTOR), JAK2 and PI3K [56] (Fig. 4).
Given that EPO is a renal hormone, the kidney likely plays
an important role in bone formation and fracture healing
via EPO.
Fig. 3 Actions of BMP-7 on
bone. Kidney produces BMP-7.
BMP-7 stimulates chondrocyte
and osteoblast differentiation
from MSC; it also induces their
osteogenesis. : produce or
promote, : inhibit, BMP:
bone morphogenetic protein,
MSC: mesenchymal stem cell
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Other factors that are involved in the regulation
of bone remodeling
Osteoprotegerin, secreted by osteoblast lineage cells,
belongs to the tumor necrosis factor (TNF) family of
receptors [57]. Known as a decoy receptor for the pro-
osteoclastic cytokine RANKL, OPG can inhibit osteoclast
differentiation and activation. Clinical studies indicate that
the levels of OPG are increased in patients with CKD
stages I through V and that serum levels of OPG correlate
with serum creatinine levels and have a reciprocal rela-
tionship to creatinine clearance over a 24-h period [58].
Furthermore, OPG levels drop to laboratory norms after
renal transplantation in parallel with renal function
restoration [59]. Thus, the kidney is recognized as the
major site for clearance of OPG.
Sclerostin, another bone formation regulator, is secreted
by osteocytes. As an antagonist for BMPs and Wnt sig-
naling, sclerostin can modulate the activity of osteoblasts
by reducing ALP activity, synthesis of type I collagen and
mineralization [60, 61]. In addition, sclerostin can also
promote osteoblast apoptosis in vitro [62]. Recent studies
show that serum sclerostin levels are increased in patients
with CKD and are negatively correlated with estimated
glomerular filtration rate (eGFR) following correction for
age and gender. Moreover, the elevated serum sclerostin
levels reduce rapidly in parallel with the improvement of
renal function, which suggests that the kidney probably
participates in sclerostin clearance [63, 64]. Therefore, the
kidney can also regulate bone formation by clearing some
bone regulators.
In addition, parathyroid hormone (PTH) and FGF-23 are
key regulators in mediating bone and mineral abnormalities
caused by CKD. Both PTH and FGF-23 begin to increase
in the early stage of CKD, when the eGFR drops below
60 ml/min per 1.73 m2 [65]. Early control PTH and FGF-
23 can improve bone and mineral disturbances in CKD
effectively [66, 67]. PTH, on the one hand, can increase the
number and activity of osteoclasts by regulating the
expression of RANKL and OPG [68]; on the other hand, it
can suppress chondrocyte and osteoblast differentiation
manifested as reduced mineralization, and decreased
expression of Runx2, ALP, procollagen I and osteocalcin
via cAMP/PKA and Ca2?/PKC signaling pathways [69–
71]. Apart from these effects, PTH can interact with
mediators between the kidney and bone, such as
1,25(OH)2D3, FGF-23 and calcium. The decline of renal
function results in the deficiency of 1,25(OH)2D3 and
subsequent decrease of serum calcium, which increase the
synthesis and secretion of PTH and even the hyperplasia of
parathyroid gland through VDR and CaSR/IP3 mediated
signaling pathways, respectively [7, 72]. The PTH can
inversely increase serum calcium by promoting its reab-
sorption by the kidney and release from bone; it can also
increase 1,25(OH)2D3 levels by stimulating its production
and inhibiting its degeneration in the kidney [73, 74].
Furthermore, elevated PTH can increase FGF-23 expres-
sion in bone either by activation of PKA and Wnt signaling
pathways in osteoblasts or by promoting 1,25(OH)2D3
production [22, 75]. Meanwhile, the parathyroid gland is
one of the target organs of FGF-23 and it can inhibit PTH
synthesis either by cooperating with Klotho or via mitogen-
Fig. 4 Actions of EPO on bone. EPO produced by the kidney
promotes osteoblast activity, stimulates chondrocyte proliferation and
angiogenesis and decreases osteoclast activity by binding EPO-R.
EPO stimulates osteoblast and osteoclast differentiation from their
precursors by up-regulating BMP2 expression by HSC and stimulates
osteoblast differentiation from MSC by binding EPO-R or CD131.
: produce or promote, : inhibit, BMP: bone morphogenetic
proteins, EPO: erythropoietin, EPO-R: erythropoietin receptor, HSC:
hematopoietic stem cell, MSC: mesenchymal stem cell
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activated protein kinases (MAPK) and calcineurin-medi-
ated pathways independently [76, 77]. Therefore, there are
several negative feedback loops between these factors, and
their interactions play a very important role in the crosstalk
between the kidney and bone.
Conclusion
The kidney and bone are tightly coupled from early
embryonic development, and the relationship between
them is far more complex. The kidney affects bone
development, remodeling and repair by regulating calcium
and phosphate homeostasis, producing cytokines and
clearing bone regulators (Fig. 5). As all of these actions
have pleiotropic effects not only on bone but also on other
tissues or organs, to fully understand their diverse impacts
is difficult. However,it at least gives us some hints that
kidney diseases should be taken into consideration when
patients present with osteodystrophy and disturbances in
bone and mineral metabolism. For some of these patients,
treatment for renal dysfunction may accelerate their
recovery. Finally, we hope that new discoveries of the roles
played by renal cytokines in bone and an increased
awareness of the underlying pathophysiologic mechanisms
will pave the way for more individualized therapies.
Fig. 5 The kidney affects bone development, remodeling and repair
by regulating calcium and phosphate homeostasis, producing cytoki-
nes and clearing bone regulators. (1) The kidney reabsorbs calcium
and phosphate via TRPV6 and NaPi IIa/c. Calcium and phosphate are
not only components of bone but also exert direct effects on bone
cells via CaSR mediated signaling pathways. (2) The kidney
synthesizes 1,25(OH)2D3, which can increase calcium and phosphate
absorption and reabsorption by stabilizing their transporters. It can
also exert direct effects on bone via VDR mediated signaling
pathways and increase FGF-23 production in bone. (3) The kidney
produces Klotho, which functions as a collaborator with bone-derived
FGF-23 to decrease 1,25(OH)2D3 or exerts direct effects on bone
independently. (4) The kidney produces BMP-7, which can exert
direct effects on bone by activating Smad1/4/5/8 or TAK1/MKK/p38
signaling pathways. (5) The kidney synthesizes EPO, which has both
direct effects on bone by activating JAK2, mTOR and PI3K signaling
pathways and indirect effects through bone marrow. (6) OPG and
sclerostin are bone-derived bone regulators. They are mainly cleared
in the kidney. (7) PTH mediates the crosstalk between the kidney and
bone. There are several feedback loops between PTH and serum
calcium, 1,25(OH)2D3 and FGF-23. : produce or promote, :
inhibit, (red arrow) represents the effects of kidney,
(yellow arrow) represents the effects of bone, (black arrow)
represents the effects of others, (pink box with up arrow)
represents up-regulation or promotion, (blue box with down
arrow) represents down-regulation or inhibition, 1a(OH)ase: 1a-
hydroxylase, ADAMTMS: a disintegrin and metalloproteinase with
thrombospondin motifs, ALP: alkaline phosphatase, BMP: bone
morphogenetic protein, Ca2?: calcium, CaSR: calcium-sensitive
receptor, ECM: extracellular matrix, FGF: fibroblast growth factor,
HSC: hematopoietic stem cell, MMP: metalloproteinase, MSC:
mesenchymal stem cell, OBL: osteoblast, OCL: osteoclast, OPG:
osteoprotegerin, PO4: phosphate, PTH: parathyroid hormone,
RANKL: receptor activator of nuclear factor NF-jb ligand, Runx2:
runt-related gene 2, VDR: vitamin D receptor, VEGF: vascular
endothelial growth factor
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